Market reactionShares fell 11% on Nov 5.
Insight Molecular Diagnostics (iMDx) develops GraftAssure blood tests that detect kidney transplant rejection; its test kit for hospital labs, GraftAssureDx, awaits FDA authorization.
iMDx's case rests on GraftAssureDx, a test kit that lets transplant hospitals measure donor DNA in blood to spot kidney rejection in-house. It submitted a De Novo request to FDA in March 2026; in late July FDA asked for more information, and authorization is still pending. Medicare coverage for surveillance testing widened in July. Revenue was $239,000 in the second quarter. Cash was $17.8 million at June 30 after $16.9 million of first-half operating cash use, though management says it has at least 12 months of funding.
Thesis checklist
2 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA authorizes GraftAssureDx
Does FDA authorize GraftAssureDx for kidney transplant rejection testing?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
GraftAssureDx still awaits FDA authorization, with little revenue until kits can be sold
Medicare coverage unlocked, FDA clearance pending — GraftAssure's commercial future depends on authorization before cash runs out
GraftAssure's FDA de novo clearance for kidney transplant rejection testing is the binary event that defines IMDX's commercial viability
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Other cancers, Kidney diseases, Obesity, diabetes and heart disease, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
2 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.